Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc. is well-positioned in the biopharmaceutical sector, particularly in metabolic and endocrine disorders, with a robust pipeline featuring VK2809, VK5211, and VK0214, which are poised for significant clinical developments. The company's strategic transactions are expected to enhance its clinical updates and options, thereby improving investor sentiment ahead of important clinical readouts, with products like VK2735 and an upcoming amylin agonist IND likely to attract favorable partnerships. Furthermore, as the market for independent, late-stage metabolic therapeutics narrows, Viking's maturity and strong data positions the company to capitalize on increased investor interest and potential premium valuations.

Bears say

Viking Therapeutics Inc is currently exposed to significant risks typical of the biopharmaceutical industry, including unpredictable clinical trial outcomes and regulatory uncertainties, which can negatively impact its stock performance. Additionally, the increasingly complex and price-sensitive nature of commercial markets for its product candidates could further undermine financial prospects. Heightened scrutiny of licensing deals in the biotech sector, particularly between the U.S. and China, adds another layer of risk that may adversely affect investor confidence in the company’s growth trajectory.

Viking Therapeutics (VKTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 10 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.